Marex Group’s Fulcrum Therapeutics FULC Stock Holding History

Marex Group’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-42,000	Closed	-$322K	–	1221
2026 Q1	$322K	Buy	+42,000	New	+$390K	﹤0.01%	753

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marex Group's FULC Position: Q2 2026 in Review

Marex Group sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 42,000 shares — an estimated $322K sold.

Marex Group first reported a position in FULC in Q1 2026 and held it in 1 quarter. The position peaked at $322K in Q1 2026. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Marex Group reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
Marex Group sold 42,000 Fulcrum Therapeutics shares in Q2 2026, an estimated $322K.
Marex Group first reported a position in Fulcrum Therapeutics in Q1 2026 and held it in 1 quarter.
Marex Group's Fulcrum Therapeutics position peaked at $322K in Q1 2026.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.